Tudor Investment Corp ET AL Has $391,000 Holdings in FibroGen, Inc (FGEN)

Tudor Investment Corp ET AL boosted its holdings in FibroGen, Inc (NASDAQ:FGEN) by 7.1% in the second quarter, according to its most recent filing with the SEC. The institutional investor owned 12,095 shares of the biopharmaceutical company’s stock after buying an additional 799 shares during the period. Tudor Investment Corp ET AL’s holdings in FibroGen were worth $391,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. Prudential Financial Inc. increased its stake in FibroGen by 9.6% in the 2nd quarter. Prudential Financial Inc. now owns 448,780 shares of the biopharmaceutical company’s stock worth $14,496,000 after buying an additional 39,430 shares in the last quarter. Principal Financial Group Inc. increased its stake in FibroGen by 0.4% in the 1st quarter. Principal Financial Group Inc. now owns 136,045 shares of the biopharmaceutical company’s stock worth $3,354,000 after buying an additional 504 shares in the last quarter. FMR LLC increased its stake in FibroGen by 96.9% in the 2nd quarter. FMR LLC now owns 3,335,997 shares of the biopharmaceutical company’s stock worth $107,753,000 after buying an additional 1,641,423 shares in the last quarter. Citigroup Inc. increased its stake in FibroGen by 37.3% in the 2nd quarter. Citigroup Inc. now owns 40,046 shares of the biopharmaceutical company’s stock worth $1,294,000 after buying an additional 10,876 shares in the last quarter. Finally, Teachers Advisors LLC increased its stake in FibroGen by 1.4% in the 1st quarter. Teachers Advisors LLC now owns 468,413 shares of the biopharmaceutical company’s stock worth $11,546,000 after buying an additional 6,512 shares in the last quarter. Institutional investors and hedge funds own 47.49% of the company’s stock.

A number of equities research analysts have issued reports on the company. Citigroup Inc. increased their price target on FibroGen from $48.00 to $65.00 and gave the stock a “top pick” rating in a research note on Tuesday, August 8th. Mizuho assumed coverage on FibroGen in a research report on Wednesday, October 4th. They set a “neutral” rating and a $61.00 price objective for the company. BidaskClub lowered FibroGen from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 31st. Stifel Nicolaus restated a “buy” rating and set a $80.00 price objective on shares of FibroGen in a research report on Thursday, September 14th. Finally, William Blair restated an “outperform” rating on shares of FibroGen in a research report on Wednesday, August 9th. Two equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $65.67.

COPYRIGHT VIOLATION NOTICE: “Tudor Investment Corp ET AL Has $391,000 Holdings in FibroGen, Inc (FGEN)” was first reported by Ticker Report and is the sole property of of Ticker Report. If you are viewing this report on another site, it was illegally copied and reposted in violation of United States and international copyright and trademark law. The legal version of this report can be read at https://www.tickerreport.com/banking-finance/2957235/tudor-investment-corp-et-al-has-391000-holdings-in-fibrogen-inc-fgen.html.

In related news, CEO Thomas B. Neff sold 18,900 shares of the company’s stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $54.45, for a total transaction of $1,029,105.00. Following the completion of the sale, the chief executive officer now owns 3,217,455 shares of the company’s stock, valued at approximately $175,190,424.75. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider K Peony Yu sold 15,000 shares of the company’s stock in a transaction dated Wednesday, October 4th. The shares were sold at an average price of $60.00, for a total transaction of $900,000.00. The disclosure for this sale can be found here. Insiders have sold 552,828 shares of company stock valued at $26,593,147 in the last three months. Corporate insiders own 14.90% of the company’s stock.

FibroGen, Inc (NASDAQ FGEN) opened at 55.825 on Friday. The stock’s 50 day moving average price is $51.43 and its 200-day moving average price is $36.02. FibroGen, Inc has a 12 month low of $15.60 and a 12 month high of $60.15. The stock’s market cap is $3.97 billion.

FibroGen (NASDAQ:FGEN) last released its earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.48) EPS for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.01). The company had revenue of $29.00 million for the quarter, compared to analysts’ expectations of $34.80 million. FibroGen had a negative return on equity of 64.42% and a negative net margin of 105.59%. Equities analysts expect that FibroGen, Inc will post ($1.81) EPS for the current year.

FibroGen Company Profile

FibroGen, Inc is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.

Want to see what other hedge funds are holding FGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for FibroGen, Inc (NASDAQ:FGEN).

Institutional Ownership by Quarter for FibroGen (NASDAQ:FGEN)

Receive News & Ratings for FibroGen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2017 Ticker Report. Google+.